InvestorsHub Logo
Followers 18
Posts 642
Boards Moderated 0
Alias Born 05/19/2017

Re: None

Wednesday, 11/30/2022 3:16:12 AM

Wednesday, November 30, 2022 3:16:12 AM

Post# of 461851
This was a year ago…

“Three F.D.A. Advisers Resign Over Agency’s Approval of Alzheimer’s Drug
The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients.”

https://www.nytimes.com/2021/06/10/health/aduhelm-fda-resign-alzheimers.html

No safety concerns for Anavex Life Sciences, but Easai/Biogen have dumped vast sums of money into PR for BAN2401. Probably just to get out ahead of 2-73.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News